| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
|
Ann N Y Acad Sci
|
2013
|
2.03
|
|
2
|
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
|
Cancer Immun
|
2013
|
1.71
|
|
3
|
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
|
PLoS One
|
2014
|
1.37
|
|
4
|
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
|
Nat Rev Rheumatol
|
2015
|
1.11
|
|
5
|
Immunomodulatory therapy for melanoma: ipilimumab and beyond.
|
Clin Dermatol
|
2013
|
1.04
|
|
6
|
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
|
Clin Cancer Res
|
2014
|
1.01
|
|
7
|
Clinical impact of checkpoint inhibitors as novel cancer therapies.
|
Drugs
|
2014
|
0.99
|
|
8
|
Immune checkpoint inhibitors in clinical trials.
|
Chin J Cancer
|
2014
|
0.98
|
|
9
|
Cancer immunotherapy in clinical practice -- the past, present, and future.
|
Chin J Cancer
|
2014
|
0.98
|
|
10
|
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
|
J Clin Invest
|
2015
|
0.98
|
|
11
|
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
|
Toxins (Basel)
|
2014
|
0.92
|
|
12
|
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
|
Cancer Immunol Res
|
2015
|
0.86
|
|
13
|
Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies.
|
Semin Oncol
|
2015
|
0.83
|
|
14
|
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).
|
Oncol Rep
|
2014
|
0.82
|
|
15
|
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
|
Oncologist
|
2015
|
0.81
|
|
16
|
Novel dendritic cell-based vaccination in late stage melanoma.
|
Hum Vaccin Immunother
|
2014
|
0.79
|
|
17
|
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
|
Ther Adv Med Oncol
|
2015
|
0.78
|
|
18
|
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
|
Dermatol Ther (Heidelb)
|
2015
|
0.78
|
|
19
|
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
|
Mod Pathol
|
2015
|
0.77
|
|
20
|
The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.
|
Cancers (Basel)
|
2015
|
0.75
|